Technical Analysis for AGEN - Agenus Inc.

Grade Last Price % Change Price Change
grade A 5.06 4.33% 0.21
AGEN closed up 4.33 percent on Friday, February 23, 2018, on 1.47 times normal volume. Due to the stock's strong uptrend, it may remain overbought for a while. So, if you're looking for a reason to sell, don't put too much weight on it being overbought.
7 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Strong Up Up Up
See historical AGEN trend table...

Date Alert Name Type % Chg
Feb 23 Upper Bollinger Band Walk Strength 0.00%
Feb 23 Wide Bands Range Expansion 0.00%
Feb 23 Above Upper BB Strength 0.00%
Feb 23 Overbought Stochastic Strength 0.00%
Feb 23 Up 3 Days in a Row Strength 0.00%
Feb 23 Up 4 Days in a Row Strength 0.00%
Feb 23 Up 5 Days in a Row Strength 0.00%
Feb 23 Upper Bollinger Band Touch Strength 0.00%
Feb 22 Calm After Storm Range Contraction 4.33%
Feb 22 Upper Bollinger Band Walk Strength 4.33%

Older signals for AGEN ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Agenus Inc., a biotechnology company, engages in developing and commercializing technologies to treat cancers and infectious diseases. Its technology portfolio consists of saponin adjuvant based technologies and heat shock protein based technologies. The company offers Oncophage vaccine for the treatment of renal cell carcinoma in patients at intermediate risk of recurrence. Its products under development include QS-21 Stimulon adjuvant, which is in Phase III clinical trials for the treatment of malaria, melanoma, non-small cell lung cancer, and shingles, as well as for the treatment of various infectious diseases, multiple cancer types, and Alzheimer's disease; and HerpV, a therapeutic vaccine candidate that is in Phase 2 clinical trial for the treatment of genital herpes. The company's products under development also comprise Prophage series of cancer vaccines, including R-series candidates in RCC, M-series candidates in melanoma, and G-series candidates in glioma. Its Prophage series of cancer vaccines were tested in Phase III clinical trials for the treatment of renal cell carcinoma and metastatic melanoma; and are in Phase I and Phase II clinical trials for various indications, and in Phase II clinical trials for the treatment of diagnosed and recurrent glioma. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.
Is AGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 4 bullish, 0 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.45
52 Week Low 3.2
Average Volume 1,380,125
200-Day Moving Average 3.9182
50-Day Moving Average 3.8006
20-Day Moving Average 3.9965
10-Day Moving Average 4.301
Average True Range 0.2553
ADX 32.32
+DI 36.87
-DI 6.42
Chandelier Exit (Long, 3 ATRs ) 4.3141
Chandelier Exit (Short, 3 ATRs ) 4.2859
Upper Bollinger Band 4.9318
Lower Bollinger Band 3.0612
Percent B (%b) 1.07
BandWidth 46.805955
MACD Line 0.2789
MACD Signal Line 0.1412
MACD Histogram 0.1377
Fundamentals Value
Market Cap 504.54 Million
Num Shares 99.7 Million
EPS -1.26
Price-to-Earnings (P/E) Ratio -4.02
Price-to-Sales 8.62
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.48
Resistance 3 (R3) 5.44 5.26 5.41
Resistance 2 (R2) 5.26 5.15 5.28 5.39
Resistance 1 (R1) 5.16 5.09 5.21 5.20 5.36
Pivot Point 4.98 4.98 5.01 5.00 4.98
Support 1 (S1) 4.88 4.87 4.93 4.92 4.76
Support 2 (S2) 4.70 4.81 4.72 4.73
Support 3 (S3) 4.60 4.70 4.71
Support 4 (S4) 4.64